Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - amisulbrom - unknown - amisulbrom active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nissan chemical corporation - amisulbrom - unknown - amisulbrom active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nissan chemical corporation - amisulbrom - unknown - amisulbrom active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - amisulbrom - water dispersible granule - amisulbrom active 500.0 g/kg - fungicide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - amisulbrom; copper (cu) present as tribasic copper sulphate - suspension concentrate - amisulbrom active 32.0 g/l; copper (cu) present as tribasic copper sulphate mineral-copper active 180.0 g/l - fungicide

New Zealand - English - Ministry for Primary Industries

nufarm limited - amisulbrom - amisulbrom 500 g/kg - fungicide

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; methylcellulose; lactose monohydrate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; methylcellulose; magnesium stearate; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: macrogol 6000; methylcellulose; purified talc; magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; basic butylated methacrylate copolymer; titanium dioxide; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.